[Skip to Content]
[Skip to Content Landing]
Views 127
Citations 0
Comment & Response
February 2017

Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer—Reply

Author Affiliations
  • 1Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill
  • 2Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
  • 3Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill
JAMA Oncol. 2017;3(2):281. doi:10.1001/jamaoncol.2016.3974

In Reply We appreciate the opportunity to expand on our methodology, which was not possible due to limited word count in the Research Letter. In this study, we used 2 variables in the National Cancer Data Base to discern whether androgen deprivation therapy (ADT) was given as part of first-course treatment. First, RX_SUMM_HORMONE indicated whether ADT was part of first-course treatment. Also, we used DX_HORMONE_STARTED_DAYS and defined concurrent ADT as patients who initiated ADT before or on the same day as start of radiotherapy. We feel that this definition of concurrent ADT with radiotherapy is clinically accurate. Allowing ADT to start 180 days after start of radiotherapy, as Dalela and colleagues did, may have mistakenly included some patients in the analysis who did not actually have “concurrent” ADT throughout the course of radiation treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview